AlphAIAlphAI — Financial news for AI agents
StockNASDAQ · US · USDHealthcare · Biotechnology

$ARTV

Artiva Biotherapeutics, Inc.

Price · $ARTVvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $ARTV in the last 7 days.

Insider · 30dAll trades →
Buys
—
0 txs
Sells
$1.3M
6 txs
Banerjee Subhashis2× · $111K
10b5-1 share of filings33%
See all $ARTV insider activity →
Top stories · $ARTVMore →
SEP 11·SEC EDGAR 8-KLow

Artiva Biotherapeutics, Inc. (ARTV): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Artiva Biotherapeutics, Inc. (ARTV) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (e) On September 8, 2026, the Company held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Me

SEP 4·SEC EDGAR

Horan Christopher sold $116K of ARTV

Horan Christopher (Chief Tech Operations Officer) sold 10,366 shares of Artiva Biotherapeutics, Inc. (ARTV) at $11.16 ($0.12M total) on 2026-09-03.

SEP 4·SEC EDGAR

Aslan Fred sold $690K of ARTV

Aslan Fred (Chief Executive Officer) sold 61,888 shares of Artiva Biotherapeutics, Inc. (ARTV) at $11.16 ($0.69M total) on 2026-09-03.

ARTV sentiment & insider activity

Recent ARTV coverage spans insider activity, corporate actions and earnings.

In the last 30 days, ARTV insiders filed 6 SEC Form 4 transactions — no purchases and 6 sales ($1.3M). The most active reporter was Banerjee Subhashis, Chief Medical Officer, with 2 filings. 33% of those filings were made under pre-arranged Rule 10b5-1 plans.

What's driving ARTV

  • Potential dilution from increased share reserve and new warrant inclusion; governance change may affect investor perception.

    SEC EDGAR 8-K · Sep 11, 2026

  • Insider sale of modest size by a senior officer.

    SEC EDGAR · Sep 4, 2026

  • Insider sell by the CEO may signal reduced confidence, but the amount is modest relative to holdings.

    SEC EDGAR · Sep 4, 2026

  • The filing adds concrete regulatory and clinical-development milestones alongside a large cash balance, improving visibility into the Phase 3 timeline and funding runway.

    SEC EDGAR 8-K · Aug 6, 2026

  • This is a disclosed insider-adjacent fund purchase, but it is not a company fundamental update; it may slightly affect near-term sentiment/liquidity expectations.

    SEC EDGAR · Jul 31, 2026

AlphAI scores every news story that mentions ARTV with an AI model for sentiment and relevance, and aggregates insider trades from Artiva Biotherapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $ARTV

Score
SEP 11$ARTVLowSEC EDGAR 8-K

Artiva Biotherapeutics, Inc. (ARTV): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Artiva Biotherapeutics, Inc. (ARTV) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (e) On September 8, 2026, the Company held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Me

1 min read
AUG 6$ARTVMedSEC EDGAR 8-K

Artiva Biotherapeutics, Inc. (ARTV): Results of Operations and Financial Condition

Artiva Biotherapeutics, Inc. (ARTV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights Clinical, safety and translational data presented at EULAR 2026 reinforced AlloNK®’s potential to drive deep B-cell depletion and meaningful clinical activity, with a

6 min read
JUL 24$ARTVLowinvesting.com

Thursday’s insider buys and sells: Artiva, StoneX and CoreWeave By Investing.com

A roundup of SEC-reported insider trades for US-listed firms. RA Capital Management bought about $2.58M of Artiva Biotherapeutics (ARTV). Byrna Technologies (BYRN) saw board chair and CEO buy about $179k and $77k. Aqua Capital bought about 120k Energizer (ENR) shares. StoneX (SNEX) insiders sold about $7.8M, $3.89M, and $7.13M. CoreWeave (CRWV) CEO sold about $24.1M under a 10b5-1 plan; Travelers (TRV) CFO sold about $6.01M.

4 min read

Related tickers

More in Biotechnology